“从制度保障上提供可能,可以有足够的渠道和能力引进优秀、高端的人才,从而出新药、出好药、出快速药。”改革,再次让2015年的上海药物所收获颇丰:成功转让15项新药研发成果,合同总金额达到8亿元;获得5个1.1类新结构化学药物的临床批件;攻克“G蛋白偶联受体(GPCR)药靶研究”的信号传导科学难题,获评中科院“十二五”重大标志性科技成果。上海药物所副所长叶阳总结这一年的努 “From the system to provide security, there may be sufficient channels and the ability to introduce excellent, high-end talent, so that a new drug, a good drug, a fast medicine.” “Reform, once again let the Shanghai drug harvest in 2015 : Successful transfer of 15 new drug research and development achievements, the total contract amount of 800 million yuan; access to five 1.1 new structural chemical drugs in clinical approval; ”G protein-coupled receptor (GPCR) drug target research“ signal transmission Scientific problems, won the CAS ”Twelve-Five " major landmark scientific and technological achievements. Ye Yang, deputy director of the Shanghai Institute of Drug summing up this year’s efforts